Life Sciences BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL AIT News Desk Jun 13, 2022 Following Additional Data Submission to FDA Demonstrating ORR Superiority Over Ibrutinib As Determined by IRC, PDUFA Goal Date Extended to…
Healthcare Management BeiGene And NewBridge Pharmaceuticals Announce Approval In Saudi Arabia Of BRUKINSA (Zanubrutinib)… AIT News Desk Nov 15, 2021 BRUKINSA is now approved for the treatment of MCL in 11 countries and regions, including the United States, China, Canada, Australia, Brazil, the…